Employer Health Costs Set to Rise 8.2% in 2027, the Steepest Jump Since 2003

Employers should brace for the sharpest jump in health benefit costs in more than two decades. Marsh, formerly Mercer, projects an 8.2% increase in 2027, the highest rate since 2003, according to preliminary results from the firm's 2026 National Survey of Employer-Sponsored Health Plans. The findings draw on responses from more than 1,800 employers as of Aug. 10.

This is not a one-year anomaly. It marks the fifth consecutive year of rising costs, following a decade of what analysts called "more moderate annual increases." It is also the steepest increase within that five-year stretch. The trend line is unambiguous: costs are compounding, and the rate of compounding is accelerating.

The number gets worse before any mitigation is applied. Employers estimate that if they took no action at all, the cost of maintaining current plans would climb 11% in 2027. The 8.2% figure already assumes some belt-tightening. Without it, the increase would push well into double digits.

What's Driving the Spike

Several forces are converging at once, and none of them are new, but their combined weight is unusual. Provider consolidation continues to reduce competitive pricing pressure in local markets. Government funding has not kept pace with medical inflation, shifting more cost burden onto employer-sponsored plans. Advanced treatments, often expensive by design, are entering broader use. Artificial intelligence software used in claims processing is also cited as a contributing cost factor, an interesting wrinkle given AI's reputation elsewhere as a cost-saving tool.

Then there are GLP-1 medications, the weight-loss and diabetes drugs that have reshaped pharmacy benefit budgets over the past few years. Marsh's actuaries estimate rising GLP-1 utilization accounts for a full percentage point of the overall 2027 cost growth on its own. That is a meaningful chunk of an already elevated figure.

The dynamics around these drugs are shifting, though not uniformly in employers' favor. "While the market for these medications is evolving in ways that could ultimately result in lower costs, some employers needing immediate cost relief chose to drop this coverage for next year," analysts wrote in the report. In other words, some employers are cutting a benefit that workers have come to expect, betting that near-term savings outweigh the retention and morale risk.

A less obvious driver sits inside a nine-year-old federal law. The No Surprises Act's Independent Dispute Resolution process, designed to settle billing disputes between insurers and out-of-network providers, has produced what Marsh calls an "unintended consequence." Total costs tied to that IDR process hit $22.4 billion by the end of 2025, according to a recent analysis. A mechanism built to protect patients from surprise bills has itself become a cost center, and that cost eventually flows back into premiums.

Employers are not standing still. Fifty-nine percent plan to make cost-cutting changes to their health benefits next year, ranging from plan design adjustments to narrower networks or higher cost-sharing. Simon Camaj, Marsh's U.S. health and benefits leader, framed the calculus bluntly in a statement: "Few organizations can absorb health cost increases that outpace inflation without making difficult financial decisions."

Those difficult decisions have direct implications for workers. Plan design changes typically mean higher deductibles, narrower drug formularies, or increased employee contributions. When 59% of employers are actively looking to shift costs, the burden does not simply vanish. It moves, usually toward the workforce, and often in ways that are less visible than a headline premium increase but no less real for household budgets.

Marsh's numbers are not an outlier either. A separate August report from Aon projected employer healthcare costs would spike 9.5% in 2027, lifting average per-employee costs above $19,000. Aon's analysts noted that would mark the fourth straight year in which costs rose by or near double digits. Two independent surveys, using different methodologies and employer samples, are pointing in the same direction with similar magnitude. That convergence matters. When two major benefits consultancies land within roughly a point and a half of each other on a multi-year trend, the signal is harder to dismiss as noise.

The broader context here is a labor market where compensation increasingly means more than base salary. Health benefits are a substantial and growing share of total employee compensation cost, and when that share rises faster than wages or inflation, it squeezes the room employers have to raise pay elsewhere. Workforce economics in 2027 will be shaped as much by what happens to health plan design as by headline wage growth.

The Bottom Line

An 8.2% increase, or 11% without intervention, is not a rounding error. It is the kind of number that forces trade-offs between benefit generosity, wage growth, and headcount. Employers facing a fifth straight year of accelerating health costs have fewer levers left to pull without touching the employee-facing side of the equation directly. GLP-1 coverage decisions, IDR-related billing costs, and provider consolidation are structural pressures, not cyclical ones, and none show signs of easing. For workers, the practical outcome is likely to be higher deductibles, narrower networks, and benefit trims dressed up as plan design optimization. For employers, the math is getting harder every year, and the easy fixes were exhausted several cycles ago.